Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

10.59

Margin Of Safety %

34

Put/Call OI Ratio

0.26

EPS Next Q Diff

-0.35

EPS Last/This Y

-6.12

EPS This/Next Y

0.48

Price

53.83

Target Price

68.42

Analyst Recom

1.17

Performance Q

19.65

Relative Volume

0.71

Beta

2.33

Ticker: PTGX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04PTGX51.050.920.718522
2025-07-07PTGX49.870.930.948508
2025-07-08PTGX49.70.930.378512
2025-07-09PTGX52.30.940.028467
2025-07-10PTGX52.860.930.108508
2025-07-11PTGX53.010.931.748518
2025-07-14PTGX55.230.9215.708454
2025-07-15PTGX55.350.924.888429
2025-07-16PTGX56.630.900.148240
2025-07-17PTGX56.480.900.478231
2025-07-18PTGX55.480.900.008330
2025-07-21PTGX55.220.510.031535
2025-07-22PTGX54.990.310.002319
2025-07-23PTGX54.210.300.232367
2025-07-24PTGX53.90.260.003054
2025-07-25PTGX55.170.250.003157
2025-07-28PTGX56.280.250.153157
2025-07-29PTGX55.010.250.153157
2025-07-30PTGX54.550.255.503169
2025-07-31PTGX53.850.260.253208
2025-08-01PTGX53.80.261.003216
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04PTGX51.05-5.0- -1.65
2025-07-07PTGX49.88-5.0- -1.65
2025-07-08PTGX49.70-5.0- -1.65
2025-07-09PTGX52.29-5.0- -1.65
2025-07-10PTGX52.83-5.0- -1.65
2025-07-11PTGX53.00-5.0- -1.65
2025-07-14PTGX55.23-5.0- -1.65
2025-07-15PTGX55.32-5.0- -1.65
2025-07-16PTGX56.65-5.0- -1.65
2025-07-17PTGX56.44-5.0- -1.65
2025-07-18PTGX55.47-5.0- -1.65
2025-07-21PTGX55.23-5.0- -1.65
2025-07-22PTGX54.96-5.0- -1.65
2025-07-23PTGX54.19-5.0- -1.65
2025-07-24PTGX53.74-5.0- -1.65
2025-07-25PTGX55.15-5.0- -1.65
2025-07-28PTGX56.20-5.0- -1.65
2025-07-29PTGX55.01-5.0- -1.65
2025-07-30PTGX54.62-5.0- -1.65
2025-07-31PTGX53.86-5.0- -1.65
2025-08-01PTGX53.83-5.0- -1.65
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04PTGX-2.33-0.3110.13
2025-07-07PTGX-2.33-0.3210.13
2025-07-08PTGX-2.33-0.3210.13
2025-07-09PTGX-2.33-0.3210.13
2025-07-10PTGX-2.33-0.3210.13
2025-07-11PTGX-2.33-0.3211.54
2025-07-14PTGX-2.33-0.3611.54
2025-07-15PTGX-2.33-0.3611.54
2025-07-16PTGX-2.33-0.3611.54
2025-07-17PTGX-2.33-0.3611.54
2025-07-18PTGX-2.33-0.3611.54
2025-07-21PTGX-2.33-0.3911.54
2025-07-22PTGX-2.33-0.3911.54
2025-07-23PTGX-2.33-0.3911.54
2025-07-24PTGX-3.69-0.3911.54
2025-07-25PTGX-3.69-0.3910.60
2025-07-28PTGX-3.69-0.4210.59
2025-07-29PTGX-3.98-0.4210.59
2025-07-30PTGX-3.98-0.4210.59
2025-07-31PTGX-3.98-0.4210.59
2025-08-01PTGX-4.00-0.4210.59
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.19

Avg. EPS Est. Current Quarter

-0.5

Avg. EPS Est. Next Quarter

-0.54

Insider Transactions

-4

Institutional Transactions

-0.42

Beta

2.33

Average Sales Estimate Current Quarter

8

Average Sales Estimate Next Quarter

8

Fair Value

72.12

Quality Score

57

Growth Score

58

Sentiment Score

24

Actual DrawDown %

11.2

Max Drawdown 5-Year %

-85.8

Target Price

68.42

P/E

70.76

Forward P/E

PEG

P/S

16.06

P/B

4.84

P/Free Cash Flow

9.95

EPS

0.76

Average EPS Est. Cur. Y​

-1.65

EPS Next Y. (Est.)

-1.17

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

27.04

Relative Volume

0.71

Return on Equity vs Sector %

-15.6

Return on Equity vs Industry %

3.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.11

EBIT Estimation

Protagonist Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 124
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading